| 摘要 |
The novel cyclic urethanes, and their pharmaceutically-acceptable salts and esters, described herein which are useful as an- tiarrhythmic and antifibrillatory agents and have general structure (I), wherein (a) X is a saturated or unsaturated, 5-, 6-, or 7-membered heterocycle or carbocycle; (b) R is selected from the group consisting of covalent bond, nil, heteroatom, carbonyl, heterocyclic ring, carbocyclic ring, alkyl, alkenyl, alkoxy, alkylamino, arylalkyl, aryloxy, acyl, acyloxy, and acylamino; (c) Y is a substituted or unsubstituted, saturated or unsaturated, 5-, 6-, or 7-membere d heterocyclic ring or carbocyclic ring, or is nil; and wherein when R is nil, X and Y are fused ring systems; and when R is a covalent bond, X and Y are ring systems linked through a covalent bond; and when Y is nil, R is a covalent bond, and X is a carbocycle bound to L through R; (d) R1, R2, and R3 are independently selected from the group consisting of nil, Cl, F, Br, NH2, CF3 , OH, SO3H, CH3SO2NH, COOH, alkoxy, al- kyl, alkoxycarbonyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, acylamino, and acyloxy; (e) L is selected from the group con- sisting of alkylamino, alkenylamino, alkylimino, alkenylimino and acylamino; wherein the nitrogen atom'thereof is bound to the nitrogen atom at the 3-position of the cyclic urethanering moiety; (f ) R4 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkylacyl, and heteroalkyl; (g) A is a substituted or unsubstituted, saturated or unsaturated, straight-chain or branched, C1-C8 heteroalkyl; or a substituted or unsubstituted, saturated or unsaturated heterocycle having 6- or 7-mem- bers which may not have an oxygen atom; and A has one nitrogen atom which is adjacent to R4; and (h) R5 is a substituted or unsubstituted C1 or C2 alkyl; and the pharmaceutically-acceptable salts a nd esters thereof.
|
